Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK119 and AK112 in pMMR/MSS colorectal cancer
NCT05846867Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- May 2023
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ambuzutinib, ivonescimab in colorectal cancer (CRC), sponsored by Akeso, Inc.. Started May 2023; status: active, not recruiting.
02
Drugs
ambuzutinibivonescimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05846867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846867.